Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

MAP Pharmaceuticals, Inc. (MAPP) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 38 PAGES: 41

MAP Pharmaceuticals (MAP Pharma) is a biopharmaceutical company. It focuses on the development and commercialization of novel therapies in the field of neurology. The company's product portfolio consists of LEVADEX (dihydroergotamine, USP) inhalation aerosol, an investigational drug administered to treat migraine in adults, MAP0001 evaluated to treat asthma and chronic obstructive pulmonary diseases and MAP0001 developed for the treatment of diabetes. It's also designs novel drug delivery systems and technologies, such as, TEMPO inhaler platform, combination particle technology, stable protein & peptide technology and nebulized corticosteroid particle technology. The company operates through a single business segment. MAP Pharma is headquartered in Mountain View, California, the US. The company seeks to obtain regulatory approvals for its product candidates and advance and commercialize its portfolio.

More Info
									             MAP Pharmaceuticals, Inc. (MAPP) - Financial and Strategic SWOT
                                    Analysis Review
        Reference Code: GDPH66459FSA                                                                                          Publication Date: AUG 2012

          2400 Bayshore Parkway, Suite 200                   Phone              +1 650 3863100                  Revenue          23.1 (million USD)
          Mountain View, CA                                  Fax                +1 650 3863101                  Net Profit       -32.94 (million USD)
          94043                                              Website            www.mappharma.com               Employees        122
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           MAPP [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       MAP Pharmaceuticals (MAP Pharma) is a biopharmaceutical company. It focuses on the development and commercialization of
       novel therapies in the field of neurology. The company's product portfolio consists of LEVADEX (dihydroergotamine, USP)
       inhalation aerosol, an investigational drug administered to treat migraine in adults, MAP0001 evaluated to treat asthma and
       chronic obstructive pulmonary diseases and MAP0001 developed for the treatment of diabetes. It's also designs novel drug
       delivery systems and technologies, such as, TEMPO inhaler platform, combination particle technology, stable protein & peptide
       technology and nebulized corticosteroid particle technology.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      MAP Pharmaceuticals, Inc., SWOT Analysis
         Timothy S. Nelson                   Chief Executive Officer                  Strengths                              Weaknesses
         Thomas A. Armer, Ph.D.              Chief Scientific Officer
                                                                                      Advanced Technological Base History of Losses
         H. Ward Wolff                       Director
                                                                                      Intellectual Property Portfolio
         Scott R. Ward                       Chairman
         Matthew V. McPherron                Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Product Pipeline                       Stringent Government
       Share Data                                                                                                            Regulations
                                                                                      Changing Demographics
         MAP Pharmaceuticals, Inc.
                                                                                                                             Delay in the Planned Clinical
        Share Price (USD) as on 16-Aug-                                13.69                                                 Trials
        2012
        EPS (USD)                                                       -1.08
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                         415         GlobalData

        Enterprise Value (million USD)                                   347
        Shares Outstanding (million)                                       31
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Jul 24, 2012         MAP Pharma Reports Q2 2012 Results
                                                                                      May 04, 2012         MAP Pharma Reports Revenue Of $1m In Q1
                                                                                                           2012
                                                                                      Mar 29, 2012         MAP Pharma Reports Q4 2011 Results
                                                                                      Jan 17, 2012         MAP Pharma Appoints James O'Shea To
                                                                                                           Board
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




MAP Pharmaceuticals, Inc. (MAPP) - Financial and Strategic SWOT                                                                Reference Code: GDPH66459FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       MAP Pharmaceuticals, Inc. - Key Facts ............................................................................................................................................. 5
       MAP Pharmaceuticals, Inc. - Key Employees .................................................................................................................................... 6
       MAP Pharmaceuticals, Inc. - Key Employee Biographies .................................................................................................................. 7
       MAP Pharmaceuticals, Inc. - Major Products and Services................................................................................................................ 8
       MAP Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................... 9
          MAP Pharmaceuticals, Inc., Pipeline Products by Therapy Area.................................................................................................... 9
          MAP Pharmaceuticals, Inc., Pipeline Products by Development Phase ....................................................................................... 10
       MAP Pharmaceuticals, Inc. - History ................................................................................................................................................ 12
       MAP Pharmaceuticals, Inc. - Company Statement........................................................................................................................... 14
       MAP Pharmaceuticals, Inc. - Locations And Subsidiaries ................................................................................................................ 17
          Head Office ................................................................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 18
       MAP Pharmaceuticals, Inc. - Business Description .......................................................................................................................... 18
       MAP Pharmaceuticals, Inc. - Corporate Strategy ............................................................................................................................. 19
       MAP Pharmaceuticals, Inc. - SWOT Analysis .................................................................................................................................. 20
          SWOT Analysis - Overview........................................................................................................................................................... 20
          MAP Pharmaceuticals, Inc. - Strengths ........................................................................................................................................ 20
             Strength - Advanced Technological Base ................................................................................................................................. 20
             Strength - Intellectual Property Portfolio .................................................................................................................................... 20
             Strength - Strategic Alliances and Partnerships ........................................................................................................................ 20
          MAP Pharmaceuticals, Inc. - Weaknesses ................................................................................................................................... 20
             Weakness - History of Losses ................................................................................................................................................... 20
          MAP Pharmaceuticals, Inc. - Opportunities .................................................................................................................................. 21
             Opportunity - Product Pipeline .................................................................................................................................................. 21
             Opportunity - Changing Demographics ..................................................................................................................................... 21
             Opportunity - Emerging Markets ............................................................................................................................................... 21
          MAP Pharmaceuticals, Inc. - Threats............................................................................................................................................ 21
             Threat - Stringent Government Regulations .............................................................................................................................. 21
             Threat - Delay in the Planned Clinical Trials ............................................................................................................................. 22
             Threat - Lack of Manufacturing Facility ..................................................................................................................................... 22
       MAP Pharmaceuticals, Inc. - Key Competitors ................................................................................................................................. 23
       Section 3 – Company Financial Ratios ............................................................................................................................................. 24
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 24
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 24
       Performance Chart ........................................................................................................................................................................... 26
       Financial Performance...................................................................................................................................................................... 26
       Financial Ratios - Interim Ratios....................................................................................................................................................... 27
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 28
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 29
          MAP Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ................................................. 29
          MAP Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012................................................. 30


MAP Pharmaceuticals, Inc. (MAPP) - Financial and Strategic SWOT                                                                                                Reference Code: GDPH66459FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       MAP Pharmaceuticals, Inc., Recent Deals Summary....................................................................................................................... 31
       Section 5 – Company’s Recent Developments ................................................................................................................................ 32
          MAP Pharmaceuticals, Inc., Recent Developments...................................................................................................................... 32
             Jul 24, 2012: MAP Pharma Reports Q2 2012 Results .............................................................................................................. 32
             May 04, 2012: MAP Pharma Reports Revenue Of $1m In Q1 2012 ......................................................................................... 32
             Mar 29, 2012: MAP Pharma Reports Q4 2011 Results ..............
								
To top